expert reaction to phase 2 trial comparing psilocybin and escitalopram for depression

A study published in the New England Journal of Medicine looks at phase 2 trail comparing psilocybin, the active compound in magic mushrooms, and escitalopram, a leading antidepressant, for depression. This Roundup accompanied an SMC Briefing.   Prof Kevin McConway, Emeritus Professor of Applied Statistics, The Open University, said: “There’s…

Continue Reading expert reaction to phase 2 trial comparing psilocybin and escitalopram for depression

Phase 2 trial comparing psilocybin with escitalopram for depression

This phase 2 trial is the first head to head comparison of psilocybin against a licenced antidepressant in patients with major depressive disorder. It compares psilocybin with escitalopram in 59 patients over a 6 week period, and the findings have been published in the New England Journal of Medicine. Journalists…

Continue Reading Phase 2 trial comparing psilocybin with escitalopram for depression

Phase 2 trial comparing psilocybin with escitalopram for depression

This phase 2 trial is the first head to head comparison of psilocybin against a licenced antidepressant in patients with major depressive disorder. It compares psilocybin with escitalopram in 59 patients over a 6 week period, and the findings have been published in the New England Journal of Medicine. Journalists…

Continue Reading Phase 2 trial comparing psilocybin with escitalopram for depression

expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

The National Institute of Health and Care Excellence (NICE) have announced a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression.   Prof David Curtis, retired consultant psychiatrist and Honorary Professor at University College London and Queen Mary University of…

Continue Reading expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

The National Institute of Health and Care Excellence (NICE) have announced a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression.   Prof David Curtis, retired consultant psychiatrist and Honorary Professor at University College London and Queen Mary University of…

Continue Reading expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

The National Institute of Health and Care Excellence (NICE) have announced a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression.   Prof David Curtis, retired consultant psychiatrist and Honorary Professor at University College London and Queen Mary University of…

Continue Reading expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

The National Institute of Health and Care Excellence (NICE) have announced a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression.   Prof David Curtis, retired consultant psychiatrist and Honorary Professor at University College London and Queen Mary University of…

Continue Reading expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

The National Institute of Health and Care Excellence (NICE) have announced a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression.   Prof David Curtis, retired consultant psychiatrist and Honorary Professor at University College London and Queen Mary University of…

Continue Reading expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

The National Institute of Health and Care Excellence (NICE) have announced a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression.   Prof David Curtis, retired consultant psychiatrist and Honorary Professor at University College London and Queen Mary University of…

Continue Reading expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

The National Institute of Health and Care Excellence (NICE) have announced a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression.   Prof David Curtis, retired consultant psychiatrist and Honorary Professor at University College London and Queen Mary University of…

Continue Reading expert reaction to NICE launching a second public consultation on its draft guidance which does not recommend an Esketamine nasal spray medicine for treatment-resistant depression

End of content

No more pages to load